Introduction to Psychedelics as Medicine Program

• $222.00
• 1 mg
• Holisticcaring.com

For 30 years, MAPS – The Multidisciplinary Association for Psychedelic Studies has led the way, pursuing MDMA as the first FDA Approved therapy for treatment resistant PTSD. Johns Hopkins is working on Psilocybin treatments for end-of-life depression. Research centers around the world are participating and providers are eager to learn. This innovative new program compiles the latest research and information from around the world. Despite legal roadblocks and prohibition, people find access to these powerful medicines, and we will guide and support those ready to try.